MELA Sciences

Overview

Compare with Premier Air Charter Holdings Inc., Orchestra BioMed Holdings, Inc. or Sensus Healthcare, Inc., or pick any stock.

• TickerSSKN on NASDAQ¹
• IndustrySurgical & Medical Instruments & Apparatus¹
• HeadquartersIrvington¹
• Websitemelasciences.com
• Listed onNasdaq (MELA), Nasdaq (SSKN)¹
• Incorporated inDE⁴
• Business address5 Walnut Grove Drive, Suite 140, Horsham, Pa 19044⁴
• Filer categoryNon-accelerated filer, Smaller reporting company⁴
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Strata Skin Sciences (formerly MELA Sciences, Inc.) is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.³

Corporate structure

MELA Sciences sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What MELA Sciences reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Inventory

Properties, in its own words

We lease an 8,513 sq. ft. facility in Horsham, Pennsylvania that houses our executive offices and marketing. In August 2022, we exercised the lease renewal option and extended the term of the lease to expire in August 2026, at which time we expect to vacate the premises and transition our headquarters operations to a remote model.

We lease a 17,000 sq. ft. facility consisting of office, manufacturing and warehousing space in Carlsbad, California. We entered into a new lease in March 2024, the term of which commenced in April 2024 and expires in September 2029. Our Carlsbad facility houses the manufacturing and development operations for our excimer laser business, as well as the patient call center and reimbursement center.

Item 2 of the 10-K filed Mar 26, 2026.¹⁴

Leadership

Who has led MELA Sciences, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerRobert Joseph Moccia Mar 3, 2021 to Aug 11, 2023¹⁵
• Chief executive officerDolev Rafaeli Apr 10, 2018 to Mar 3, 2021¹⁶
• Chief executive officerFrank J. McCaney Nov 1, 2016 to Nov 28, 2016¹⁷
• Chief executive officerMichael R. Stewart Dec 16, 2015 to Feb 25, 2016¹⁸
• Chief executive officerRobert Coradini Jun 24, 2013 to Dec 10, 2013¹⁹
• Chief executive officerRosemary A. Crane Nov 13, 2013 to Feb 6, 2014²⁰
• Chief executive officerJoseph Gulfo V. Nov 14, 2007 to May 3, 2013²¹
• ChairRobert Coradini Feb 6, 2014 to Feb 6, 2014²²
• ChairJoseph Gulfo V. May 8, 2012 to May 3, 2013²³
• PresidentRobert Joseph Moccia Mar 3, 2021 to Mar 3, 2021¹⁵
• PresidentFrank J. McCaney Nov 1, 2016 to Nov 28, 2016¹⁷
• PresidentMichael R. Stewart Dec 16, 2015 to Feb 25, 2016¹⁸
• PresidentRosemary A. Crane Nov 13, 2013 to Feb 6, 2014²⁰
• PresidentJoseph Gulfo V. Nov 14, 2007 to May 3, 2013²¹
• PresidentJon I. Klippel Jun 7, 2006 to Jul 25, 2008²⁴
• PresidentWilliam R. Bronner Jun 7, 2006 to Jan 5, 2007²⁵
• PresidentChristiano S. Butler Jun 9, 2006 to May 14, 2010²⁶
• Chief financial officerChristopher Lesovitz Oct 18, 2021 to Nov 22, 2023²⁷
• Chief financial officerMathew C. Hill May 22, 2018 to Nov 13, 2020²⁸
• Chief financial officerChristina L. Allgeier Nov 12, 2015 to Jun 9, 2016²⁹
• Chief financial officerRobert W. Cook Apr 15, 2014 to Feb 4, 2015³⁰
• Chief financial officerRichard I. Steinhart May 2, 2006 to Aug 8, 2013³¹
• Chief financial officerKaren R. Krumeich Jul 26, 2006 to Jul 26, 2006³²
• Chief operating officerShmuel Gov Nov 22, 2023 to now³³
• Chief operating officerGerald D. Wagner Mar 27, 2006 to Jun 8, 2010³⁴

Former names

• MELA SCIENCES, INC. /NYMay 10, 2010 to Jan 4, 2016⁴
• ELECTRO OPTICAL SCIENCES INC /NYJun 27, 2003 to Apr 30, 2010⁴

Timeline

1. Feb 11, 20268-K Listing notice or transfer; Other events⁶⁸
2. Dec 17, 20258-K Regulation FD disclosure⁶⁹
3. Dec 10, 20258-K Shareholder vote⁷⁰
4. Nov 13, 20258-K Results of operations; Regulation FD disclosure⁷¹
5. Oct 16, 20258-K Other events⁷²
6. Oct 14, 20258-K Listing notice or transfer⁷³
7. Sep 4, 20258-K Regulation FD disclosure⁷⁴
8. Sep 3, 20258-K Entered a material agreement; Regulation FD disclosure⁷⁵
9. Aug 22, 20258-K Listing notice or transfer⁷⁶
10. Aug 18, 20258-K Regulation FD disclosure⁷⁷
11. Aug 13, 20258-K Results of operations; Regulation FD disclosure⁷⁸
12. Aug 7, 20258-K Regulation FD disclosure⁷⁹
13. Mar 3, 2021New chief executive Robert Joseph Moccia becomes CEO¹⁵
14. Apr 10, 2018New chief executive Dolev Rafaeli becomes CEO¹⁶
15. Nov 1, 2016New chief executive Frank J. McCaney becomes CEO¹⁷
16. Jan 5, 2016Went public Listed on NASDAQ¹
17. Dec 16, 2015New chief executive Michael R. Stewart becomes CEO¹⁸
18. Nov 13, 2013New chief executive Rosemary A. Crane becomes CEO²⁰
19. Jun 24, 2013New chief executive Robert Coradini becomes CEO¹⁹
20. Nov 14, 2007New chief executive Joseph Gulfo V. becomes CEO²¹
21. Jan 1, 1989Founded Founded¹

Calendar

When it reported results

1. Nov 13, 2025Reported quarterly or annual results⁷¹
2. Aug 13, 2025Reported quarterly or annual results⁷⁸
3. May 14, 2025Reported quarterly or annual results⁸⁰
4. Mar 27, 2025Reported quarterly or annual results⁸¹
5. Nov 13, 2024Reported quarterly or annual results⁸²
6. Aug 14, 2024Reported quarterly or annual results⁸³
7. Jul 11, 2024Reported quarterly or annual results⁸⁴
8. May 15, 2024Reported quarterly or annual results⁸⁵

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

208 filings to the SEC since October 2021: 8 annual reports, 13 quarterly reports, 73 major events, 53 insider forms, 13 large holders, 1 private raises, 47 other. The latest 20:

1. Mar 26, 202610-K EDGAR
2. Mar 4, 2026EFFECT EDGAR
3. Mar 4, 2026EFFECT EDGAR
4. Mar 4, 2026EFFECT EDGAR
5. Mar 2, 202615-12G EDGAR
6. Feb 27, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 EDGAR
7. Feb 27, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 EDGAR
8. Feb 27, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 EDGAR
9. Feb 27, 2026S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
10. Feb 27, 2026S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
11. Feb 27, 2026S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
12. Feb 27, 2026S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
13. Feb 27, 2026S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
14. Feb 27, 2026S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
15. Feb 27, 2026S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
16. Feb 19, 202625 EDGAR
17. Feb 11, 20268-K EDGAR
18. Dec 17, 20258-K EDGAR
19. Dec 10, 20258-K EDGAR
20. Nov 18, 20254 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

15 open-market trades by officers, directors and large owners since October 2021: 13 buys and 2 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• CVI Investments, Inc.SCHEDULE 13G/A, 2 filings Sep 8, 2025 to Nov 7, 2025⁸⁶
• Accelmed Partners, L.P.SCHEDULE 13D/A, 2 filings Jul 18, 2024 to Sep 5, 2025⁸⁷
• Lincoln Alternative Strategies LLCSCHEDULE 13G, 1 filing Sep 4, 2025⁸⁸
• 22NW Fund, LPSC 13G/A, 4 filings Jan 14, 2022 to Nov 14, 2024⁸⁹
• Nantahala Capital Management, LLCSCHEDULE 13G/A, 4 filings Feb 14, 2022 to Nov 14, 2024⁹⁰

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Jan 10, 2022Raised $480,212 in a private offering of equity⁹² Form D: 1 investor so far Form D

SEC filer profile

How MELA Sciences is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARSTRATA Skin Sciences, Inc.²
• CIK0001051514
• Employer ID (EIN)13-3986004¹⁴
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company¹⁴
• Incorporated inDelaware¹⁴
• Fiscal year endsDecember 31²
• Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus²
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance²
• Business address5 Walnut Grove Drive, Suite 140, Horsham, PA 19044²
• Phone215-619-3200²
• Shares outstanding5,888,199 shares as of Mar 16, 2026¹⁴
• Public float$3.7M as of Jun 30, 2025¹⁴
• AuditorCBIZ CPAs P.C., Philadelphia, Pennsylvania PCAOB ID 199; no auditor attestation of internal control over financial reporting¹⁴
• On EDGAR sinceJun 27, 2003²
• Filings1,076 in all: 4 (333), 8-K (291), 10-Q (61), 3 (59), SC 13G/A (44), CORRESP (41), DEF 14A (22), EFFECT (22)²
  All 45 form types

  10-K (21), SC 13G (19), UPLOAD (16), S-3 (15), 424B5 (14), PRE 14A (10), S-3/A (8), SC 13D/A (8), POS AM (7), S-8 (7), S-8 POS (7), 10-K/A (6), 424B3 (6), ARS (6), 4/A (5), 424B7 (5), 8-K/A (5), REGDEX (5), S-1/A (5), DEFA14A (3), NT 10-Q (3), SC 13D (3), CT ORDER (2), D (2), SCHEDULE 13G (2), SCHEDULE 13G/A (2), 10-Q/A (1), 15-12G (1), 25 (1), 424B4 (1), 8-A12G (1), AW (1), FWP (1), NT 10-K (1), POSASR (1), S-1 (1), SCHEDULE 13D/A (1)

• Latest filingsAnnual report (10-K) Mar 26, 2026
  Quarterly report (10-Q) Nov 14, 2025
  Proxy statement (DEF 14A) Oct 30, 2025
  Latest 8-K (8-K) Feb 11, 2026

Risk factors and legal proceedings

The risks MELA Sciences names in Item 1A of its 10-K filed Mar 26, 2026: 46 risks under these headings, as written.¹⁴

• Risks Relating to Our Business Operations
• Risks Relating to Our Common Stock
• We have incurred losses for a number of years and anticipate that we will incur continued losses for the near future.
• Our history of operating losses and current default on our long-term debt raise substantial doubt regarding our ability to continue as a going concern.
• Public health epidemics or pandemics may affect our ability to develop, market and sell our products, disrupt regulatory activities or have other adverse effects on our business and operations. In addition, public health epidemics or pandemics may adversely impact economies worldwide, which could result in adverse effects on our business, operations and prospects.
• We may not be able to maintain an uninterrupted supply of the gases used to power our lasers, as the Russia-Ukraine War has disrupted supplies of rare gases.
• We may acquire other assets or businesses, or form collaborations or make investments in other companies or technologies that could harm our operating results, dilute our stockholders’ ownership, increase our debt or cause us to incur significant expense.
• We may not be able to successfully integrate newly acquired businesses, joint ventures and other partnerships into our operations or achieve expected profitability from our acquisitions.
• Our laser treatments of psoriasis, vitiligo, atopic dermatitis and leukoderma and/or any of our future products or services may fail to gain market acceptance or be impacted by competitive products, services or therapies which could adversely affect our competitive position.
• The success of our products depends on third-party reimbursement of patients’ costs, which could result in potentially reduced prices or reduced demand and adversely affect our revenues and business operations.
• The continuing development of our products depends upon our developing and maintaining strong working relationships with physicians.
• Any failure in our customer education efforts could have a material adverse effect on our revenue and cash flow.

Legal proceedings

From time to time in the ordinary course of our business, we may be a party to certain legal proceedings, incidental to the normal course of our business. These may include controversies relating to contract claims and employment related matters, some of which claims may be material, in which case, we will make separate disclosure as required.

In the ordinary course of business, we are, from time to time, subject to audits performed by state taxing authorities. These actions and proceedings are generally based on the position that the arrangements entered into by us are subject to sales and use tax rather than exempt from tax under applicable law. We have outstanding assessments from the states of New York and California aggregating to $5.6 million including penalties and interest. The audits cover the period from August 2017 through February 2025.

In January 2021, we received notification that an administrative state judge in New York issued an opinion finding in favor of us that the sale of XTRAC treatment codes was not taxable as sales tax with respect to that state’s first assessment. The relevant taxing authority filed an appeal of the administrative law judge’s finding and, following the submission of legal briefs by both sides and oral argument held in January 2022, on May 6, 2022, we received a written decision from the Tribunal overturning the favorable sales tax determination of the administrative law judge. We appealed the Tribunal’s decision to the Appellate Division, and posted the required appellate bond in the form of cash collateral in the amount of $1.3 million. Oral argument was held by the Appellate Division on January 18, 2024.

The opening of Item 3, Legal Proceedings.¹⁴

Links

• Websitemelasciences.com¹
• WikipediaStrata Skin Sciences
• WikidataQ6715352
• SEC EDGARCIK 1051514